The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients

Ingeborg J.H. Vriens; Ashley J.R. De Bie; Maureen J.B. Aarts; Maaike de Boer; Irene E.G. van Hellemond; Joyce H.E. Roijen; Ron J.T. van Golde; Adri C. Voogd; Vivianne C.G. Tjan-Heijnen

doi:10.18632/oncotarget.14532

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients

Ingeborg J.H. Vriens, Ashley J.R. De Bie, Maureen J.B. Aarts, Maaike de Boer, Irene E.G. van Hellemond, Joyce H.E. Roijen, Ron J.T. van Golde, Adri C. Voogd and Vivianne C.G. Tjan-Heijnen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:11372-11379. https://doi.org/10.18632/oncotarget.14532

Metrics: PDF 1495 views | HTML 2478 views | ?

Abstract

Ingeborg J.H. Vriens1, Ashley J.R. De Bie1, Maureen J.B. Aarts1, Maaike de Boer1, Irene E.G. van Hellemond1, Joyce H.E. Roijen1, Ron J.T. van Golde2, Adri C. Voogd1, Vivianne C.G. Tjan-Heijnen1

1Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands

2Department of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, The Netherlands

Correspondence to:

Vivianne C.G. Tjan-Heijnen, email: [email protected]

Keywords: chemotherapy induced ovarian function failure, breast cancer, chemotherapy, ovarian insufficiency, premenopausal patients

Received: July 20, 2016 Accepted: December 26, 2016 Published: January 05, 2017

ABSTRACT

Purpose: To assess the incidence of chemotherapy-induced ovarian function failure (COFF) based on estradiol and follicle stimulating hormone (FSH) monitoring in premenopausal women with hormone-receptor positive breast cancer treated with second and third generation (neo-)adjuvant chemotherapy.

Results: We identified 115 eligible women. Two years after start of chemotherapy, COFF was significantly more often present in women ≥ 40 years (85.6%) as compared to women < 40 years (8.7%). Only age was significantly associated with COFF two years after start of chemotherapy (HR 12.26; 95% CI 5.21–28.86). In 50% of the patients, premenopausal hormone levels were the first or only evidence of ovarian function recovery (OFR).

Materials and Methods: We included all premenopausal women with hormone-receptor positive breast cancer treated with anthracycline-based chemotherapy, with or without taxanes, in our university hospital in the Netherlands in the years 2005-2013. Patients were 3-monthly monitored for ovarian function. Cox proportional hazards model was used to determine the predictive impact of various parameters on the occurrence of COFF.

Conclusions: After second- or third generation (neo-)adjuvant chemotherapy, COFF was still present in 8.7% of patients < 40 years after two years. FSH and estradiol monitoring may be relevant for those in whom ovarian function suppression is considered an additional effective endocrine treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14532

Publication Alerts

Research Papers:

The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients

Abstract